Company news
Zhejiang Starry Pharmaceutical Co., Ltd. Class A (SSE:603520) news
Zhejiang Starry Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 7, 2026: "Zhejiang Starry Pharmaceutical Co., Ltd."Announcement…
Press releases & updates
"Zhejiang Starry Pharmaceutical Co., Ltd."Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 6, 2026
"Zhejiang Starry Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Meeting of the 6th Board of Directors
August 30, 2026
"Zhejiang Starry Pharmaceutical Co., Ltd."Announcement on Results of Shareholding Reduction by the Actual Controller and Completion of Internal Share Transfer Among Persons Acting in Concert
August 13, 2026
"Zhejiang Starry Pharmaceutical Co., Ltd."Announcement on Release of Pledge over Shares Held by the Controlling Shareholder
July 16, 2026
"Zhejiang Starry Pharmaceutical Co., Ltd."Change in Equity of Shareholders with Over 5% Shares Reaching 1% Threshold
July 13, 2026
"Zhejiang Starry Pharmaceutical Co., Ltd."Announcement on Pledge of Partial Shares of Controlling Shareholder
July 7, 2026
"Zhejiang Starry Pharmaceutical Co., Ltd."Announcement on Release of the Pledge over Shares Held by the Controlling Shareholder
July 3, 2026
Announcement on Resolutions of the 1st Meeting of the 6th Board of Directors
June 15, 2026
Announcement on Convening Performance and Cash Dividend Meeting for 2025 and Q1 2026
June 8, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 28, 2026
Announcement on Election of Employee Representative Directors for the 6th Board of Directors
May 22, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 20, 2026
Announcement on Obtaining Government Subsidies
May 11, 2026
Announcement on the Actual Controller Adding a Concerted Party and a Plan for Internal Transfer of Shares among Persons Acting in Concert and Shareholding Reduction Plan
May 7, 2026
Indicative Announcement on Election of Board of Directors at Expiry of Term of Office
April 29, 2026
Announcement on Progress in Selling Equity of Joint-stock Company
April 9, 2026
Announcement on Outward Investment and Related Party Transactions
April 8, 2026
Announcement on Acquisition of Equity in Ruishi Pharmaceutical
March 23, 2026
Announcement on Release of Pledge and New Pledge of Controlling Shareholder's Shares
February 6, 2026
Announcement on Expected Increase in Performance for 2025
January 30, 2026
Announcement on Subsidiary Completing Industrial and Commercial Change Registration and Obtaining Business License
January 16, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
January 13, 2026
Announcement on Cancellation of Special Accounts for Raised Funds
December 31, 2025
Announcement on Closing Investment Projects Financed by Raised Funds, Adjusting Investment Scale, and Using Residual Raised Funds to Permanently Supplement Current Capital
December 26, 2025
Announcement on Returning All Raised Funds Temporarily Used for Supplementing Current Capital to Special Account for Raised Funds
December 22, 2025
Announcement on Returning Raised Funds Temporarily Used for Supplementing Current Capital to Special Account for Raised Funds
December 2, 2025
Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
November 25, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
November 20, 2025
Announcement on Resignation of Senior Management Members
November 3, 2025
Report for Q3 2025
October 30, 2025
Announcement on Release of Pledge of Controlling Shareholders' Shares
September 23, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 5, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 29, 2025
Full Text of 2025 Semi-annual Report
August 28, 2025
Announcement on Signing Three-party Supervision Agreement for Deposit of Raised Fund in Special Account
July 10, 2025
Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report
July 2, 2025
Announcement on Resolution of the 14th Meeting of the 5th Board of Supervisors
June 12, 2025
Announcement on Implementation of Dividend Distribution for 2024
May 29, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 22, 2025
Announcement on the Judicial Transfer of Partial Shares Held by Shareholders with over 5% Shares
May 19, 2025
Report for Q1 2025
April 29, 2025
Announcement on Correction of Annual Earnings Preannouncement for 2024
April 22, 2025
Indicative Announcement on Upcoming Judicial Auction of Shares Held by Shareholders with Over 5% Shares
March 6, 2025
Announcement on the Judicial Freezing of Partial Shares Held by Shareholders with over 5% Shares
January 26, 2025
Announcement on Completing Industrial and Commercial Change Registration and Obtaining Business License
January 23, 2025
Announcement on Resolutions of the 12th Meeting of the 5th Board of Supervisors
January 21, 2025
Annual Earnings Preannouncement for 2024
January 16, 2025
Announcement on Circulation of Restricted Shares Issued to Specific Objects
December 8, 2024
Announcement on Resolution of the 2nd Extraordinary General Meeting in 2024
November 15, 2024
Announcement on Passing On-site Inspection by FDA
November 12, 2024